You just read:

BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)

News provided by

BioMarin Pharmaceutical Inc.

Jun 30, 2017, 09:10 ET